Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11592620,elimination half-life,"The elimination half-life and the total clearance of ergovaline were found to be 56.83 +/- 13.48 min and 0.020 +/- 0.004 L/min x kg, respectively.",Toxicokinetics of ergovaline in the horse after an intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592620/),min,56.83,4212,DB00696,Ergotamine
,11592620,total clearance,"The elimination half-life and the total clearance of ergovaline were found to be 56.83 +/- 13.48 min and 0.020 +/- 0.004 L/min x kg, respectively.",Toxicokinetics of ergovaline in the horse after an intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592620/),[l] / [kg·min],0.020,4213,DB00696,Ergotamine
,31975311,globule size,"The optimized formulation exhibited a mean globule size of 160 ± 6.5 nm, zeta potential of - 20.4 ± 1.23 mV, and drug content of 99.45 ± 1.9%.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),nm,160,7126,DB00696,Ergotamine
,31975311,zeta potential,"The optimized formulation exhibited a mean globule size of 160 ± 6.5 nm, zeta potential of - 20.4 ± 1.23 mV, and drug content of 99.45 ± 1.9%.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),mv,-,7127,DB00696,Ergotamine
,31975311,zeta potential,"The optimized formulation exhibited a mean globule size of 160 ± 6.5 nm, zeta potential of - 20.4 ± 1.23 mV, and drug content of 99.45 ± 1.9%.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),mv,20.4,7128,DB00696,Ergotamine
,31975311,enhancement ratio (ER),"Ex vivo permeation studies across rat skin exhibited a significant enhancement in permeation, i.e., enhancement ratio (ER) of ~ 7.4 and 5.86 for BCM-NE and BCM-NE gel, respectively, when compared with aqueous BCM suspension gel.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),,7.4,7129,DB00696,Ergotamine
,31975311,enhancement ratio (ER),"Ex vivo permeation studies across rat skin exhibited a significant enhancement in permeation, i.e., enhancement ratio (ER) of ~ 7.4 and 5.86 for BCM-NE and BCM-NE gel, respectively, when compared with aqueous BCM suspension gel.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),,5.86,7130,DB00696,Ergotamine
,31975311,AUC0-t,"The AUC0-t for BCM-NE gel and BCM suspension was found to be 562.54 ± 77.55 and 204.96 ± 51.93 ng/ml h, respectively.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),[ng] / [h·ml],562.54,7131,DB00696,Ergotamine
,31975311,AUC0-t,"The AUC0-t for BCM-NE gel and BCM suspension was found to be 562.54 ± 77.55 and 204.96 ± 51.93 ng/ml h, respectively.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),[ng] / [h·ml],204.96,7132,DB00696,Ergotamine
,31975311,relative bioavailability (%F),The relative bioavailability (%F) of BCM was shown to be enhanced 274% by BCM-NE gel.,"Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),%,274,7133,DB00696,Ergotamine
,10965414,Cmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),,1.97,7706,DB00696,Ergotamine
,10965414,Cmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[ng] / [ml],2.05,7707,DB00696,Ergotamine
,10965414,tmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),h,1,7708,DB00696,Ergotamine
,10965414,tmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[ng] / [ml],2.05,7709,DB00696,Ergotamine
,10965414,tmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),h,0.83,7710,DB00696,Ergotamine
,10965414,AUC(0-48),"The mean AUC(0-48) were 13.6 +/- 5.0 ng.h/ml and 13.3 +/- 4.7 ng.h/ml for the test and reference treatment, respectively; the corresponding estimated treatment ratio for test: reference was 1.011, 95% CI: 0.866 to 1.142.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[h·ng] / [ml],13.6,7711,DB00696,Ergotamine
,10965414,AUC(0-48),"The mean AUC(0-48) were 13.6 +/- 5.0 ng.h/ml and 13.3 +/- 4.7 ng.h/ml for the test and reference treatment, respectively; the corresponding estimated treatment ratio for test: reference was 1.011, 95% CI: 0.866 to 1.142.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[h·ng] / [ml],13.3,7712,DB00696,Ergotamine
,30659611,Tmax,"DHE plasma levels following INP104 1.45 mg administration reached 93% of Cmax by 20 minutes and were comparable to IV DHE 1.0 mg by 30 minutes (1219 ng/mL for INP104 vs 1224 ng/mL for IV DHE), which was the Tmax for INP104.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[ng] / [ml],1219,19228,DB00696,Ergotamine
,30659611,Tmax,"DHE plasma levels following INP104 1.45 mg administration reached 93% of Cmax by 20 minutes and were comparable to IV DHE 1.0 mg by 30 minutes (1219 ng/mL for INP104 vs 1224 ng/mL for IV DHE), which was the Tmax for INP104.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[ng] / [ml],1224,19229,DB00696,Ergotamine
,30659611,Cmax,"In comparison, the Cmax for Migranal was 299.6 pg/mL (approximately 4-fold less than INP104) and occurred at 47 minutes, 17 minutes later than INP104.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[pg] / [ml],299.6,19230,DB00696,Ergotamine
,30659611,AUC0-inf,"Plasma DHE AUC0-inf were 6275, 7490, and 2199 h*pg/mL for INP104, IV DHE, and Migranal, respectively.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[h·pg] / [ml],6275,19231,DB00696,Ergotamine
,30659611,AUC0-inf,"Plasma DHE AUC0-inf were 6275, 7490, and 2199 h*pg/mL for INP104, IV DHE, and Migranal, respectively.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[h·pg] / [ml],7490,19232,DB00696,Ergotamine
,30659611,AUC0-inf,"Plasma DHE AUC0-inf were 6275, 7490, and 2199 h*pg/mL for INP104, IV DHE, and Migranal, respectively.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[h·pg] / [ml],2199,19233,DB00696,Ergotamine
,23266466,zeta potential,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),m,40.3,19967,DB00696,Ergotamine
,23266466,loading capacity,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,37.8,19968,DB00696,Ergotamine
,23266466,entrapment efficiency,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,84.2,19969,DB00696,Ergotamine
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.47,19970,DB00696,Ergotamine
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.69,19971,DB00696,Ergotamine
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.05,19972,DB00696,Ergotamine
,23266466,drug targeting index,The drug targeting index and direct transport percentage for BRC loaded CS NPs following i.n. route were 6.3 ± 0.8 and 84.2% ± 1.9%.,"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,6.3,19973,DB00696,Ergotamine
,23266466,direct transport percentage,The drug targeting index and direct transport percentage for BRC loaded CS NPs following i.n. route were 6.3 ± 0.8 and 84.2% ± 1.9%.,"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,84.2,19974,DB00696,Ergotamine
,403149,invasion half-life,The mean invasion half-life was 0.5 hours (range 0.32-1.12 hours).,Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,0.5,20609,DB00696,Ergotamine
,403149,elimination half-lives,"The mean elimination half-lives ranged from 1.4-6.2 hours for the alpha-phase and from 13 to 50 hours for the beta-phase, the longest values being observed with bromocriptine.",Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,1.4-6.2,20610,DB00696,Ergotamine
,403149,elimination half-lives,"The mean elimination half-lives ranged from 1.4-6.2 hours for the alpha-phase and from 13 to 50 hours for the beta-phase, the longest values being observed with bromocriptine.",Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,13 to 50,20611,DB00696,Ergotamine
,16618013,Cmax,Morning doses of 2 x 20 mg DHEC (reference) yielded a fast and relatively short lasting peak with a geometric mean Cmax of 2157 pg/mL (CV: 0.978) after a median tmax of 1.00 h.,Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618013/),[pg] / [ml],2157,21397,DB00696,Ergotamine
,16618013,tmax,Morning doses of 2 x 20 mg DHEC (reference) yielded a fast and relatively short lasting peak with a geometric mean Cmax of 2157 pg/mL (CV: 0.978) after a median tmax of 1.00 h.,Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618013/),h,1.00,21398,DB00696,Ergotamine
,16618013,Cmin,Cmin throughout the first 12 h was on average 189 pg/mL (CV: 0.908).,Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618013/),[pg] / [ml],189,21399,DB00696,Ergotamine
,16618013,Cmax,"There was a quite distinct diurnal effect: evening doses of 2 x 20 mg DHEC (treatment R), yielded a relatively lower exposure with geometric mean Cmax, Cav- and Cmin-values of 800 pg/mL (CV: 0.870), 389 pg/mL (0.813) and 177 pg/mL (CV: 0.942).",Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618013/),[pg] / [ml],800,21400,DB00696,Ergotamine
,16618013,Cav-,"There was a quite distinct diurnal effect: evening doses of 2 x 20 mg DHEC (treatment R), yielded a relatively lower exposure with geometric mean Cmax, Cav- and Cmin-values of 800 pg/mL (CV: 0.870), 389 pg/mL (0.813) and 177 pg/mL (CV: 0.942).",Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618013/),[pg] / [ml],389,21401,DB00696,Ergotamine
,16618013,Cmin,"There was a quite distinct diurnal effect: evening doses of 2 x 20 mg DHEC (treatment R), yielded a relatively lower exposure with geometric mean Cmax, Cav- and Cmin-values of 800 pg/mL (CV: 0.870), 389 pg/mL (0.813) and 177 pg/mL (CV: 0.942).",Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618013/),[pg] / [ml],177,21402,DB00696,Ergotamine
,10638398,relative bioavailabilities,"The relative bioavailabilities of the DHEM/RAMEB nasal spray, the DHEM/RAMEB nasal powder and the commercially available DHEM nasal spray were 25%, 19% and 21%, respectively, in comparison with i.m. administration.",Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,25,23739,DB00696,Ergotamine
,10638398,relative bioavailabilities,"The relative bioavailabilities of the DHEM/RAMEB nasal spray, the DHEM/RAMEB nasal powder and the commercially available DHEM nasal spray were 25%, 19% and 21%, respectively, in comparison with i.m. administration.",Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,19,23740,DB00696,Ergotamine
,10638398,relative bioavailabilities,"The relative bioavailabilities of the DHEM/RAMEB nasal spray, the DHEM/RAMEB nasal powder and the commercially available DHEM nasal spray were 25%, 19% and 21%, respectively, in comparison with i.m. administration.",Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,21,23741,DB00696,Ergotamine
,10638398,relative bioavailability,The relative bioavailability after oral administration was 8%.,Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,8,23742,DB00696,Ergotamine
≥,27037980,recoveries,The recoveries from spiked control samples were ≥86.16% for all analytes and IS.,"Validated liquid chromatography-tandem mass spectrometry method for simultaneous determination of clopamide, reserpine and dihydroergotoxine: Application to pharmacokinetics in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037980/),%,86.16,32966,DB00696,Ergotamine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,64,36555,DB00696,Ergotamine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,67,36556,DB00696,Ergotamine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,50,36557,DB00696,Ergotamine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,53,36558,DB00696,Ergotamine
,18534051,AUC(0-36),"Among 19 subjects, geometric mean AUC(0-36) was 6754 pg.h/mL and geometric mean AUC(0-inf) was 7483 pg.h/mL.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),[h·pg] / [ml],6754,48230,DB00696,Ergotamine
,18534051,AUC(0-inf),"Among 19 subjects, geometric mean AUC(0-36) was 6754 pg.h/mL and geometric mean AUC(0-inf) was 7483 pg.h/mL.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),[h·pg] / [ml],7483,48231,DB00696,Ergotamine
,18534051,t(max),"Geometric mean t(max) was 9.6 min, geometric mean C(max) was 3174 pg/mL, and geometric mean t((1/2)) was 9.5 h.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),min,9.6,48232,DB00696,Ergotamine
,18534051,C(max),"Geometric mean t(max) was 9.6 min, geometric mean C(max) was 3174 pg/mL, and geometric mean t((1/2)) was 9.5 h.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),[pg] / [ml],3174,48233,DB00696,Ergotamine
,18534051,t((1/2)),"Geometric mean t(max) was 9.6 min, geometric mean C(max) was 3174 pg/mL, and geometric mean t((1/2)) was 9.5 h.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),h,9.5,48234,DB00696,Ergotamine
,3732370,peak plasma concentration,A mean peak plasma concentration of 454 pg/ml was measured an average of 50 min following a 2 mg rectal dose.,Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732370/),[pg] / [ml],454,49790,DB00696,Ergotamine
,3732370,peak plasma concentration,"In contrast, the 2 mg oral dose produced a mean peak plasma concentration of 21 pg/ml an average of 69 min following the dose.",Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732370/),[pg] / [ml],21,49791,DB00696,Ergotamine
,3732370,relative bioavailability,Area under the concentration time curve indicated a relative bioavailability of 5% for the oral dosage form.,Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732370/),%,5,49792,DB00696,Ergotamine
,7548782,elimination half-life,The plasma profile of DHEK obtained after intravenous administration at a dose of 5 mg kg-1 (as base) of DHEK methane sulphonate showed a three compartment pharmacokinetic model with an elimination half-life of 6.78 h.,Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),h,6.78,51426,DB00696,Ergotamine
,7548782,absorption half-life,"The disposition of DHEK consisted of an absorption half-life of 0.02 h, a distribution half-life of 2.15 h and an elimination half-life of 5.83 h.",Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),h,0.02,51427,DB00696,Ergotamine
,7548782,distribution half-life,"The disposition of DHEK consisted of an absorption half-life of 0.02 h, a distribution half-life of 2.15 h and an elimination half-life of 5.83 h.",Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),h,2.15,51428,DB00696,Ergotamine
,7548782,elimination half-life,"The disposition of DHEK consisted of an absorption half-life of 0.02 h, a distribution half-life of 2.15 h and an elimination half-life of 5.83 h.",Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),h,5.83,51429,DB00696,Ergotamine
,7548782,absolute bioavailability,The absolute bioavailability was 4.14% after a single oral administration and 3.95% after repeated oral administrations.,Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),%,4.14,51430,DB00696,Ergotamine
,7548782,absolute bioavailability,The absolute bioavailability was 4.14% after a single oral administration and 3.95% after repeated oral administrations.,Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),%,3.95,51431,DB00696,Ergotamine
,7548782,Urinary excretion,"Urinary excretion of the unchanged drug was low (0.38% of the administered dose in the intravenous route and 0.04% in the oral route), being in agreement with a low oral bioavailability and a rapid and extensive metabolism (first-pass effect).",Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),%,0.38,51432,DB00696,Ergotamine
,7548782,Urinary excretion,"Urinary excretion of the unchanged drug was low (0.38% of the administered dose in the intravenous route and 0.04% in the oral route), being in agreement with a low oral bioavailability and a rapid and extensive metabolism (first-pass effect).",Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548782/),%,0.04,51433,DB00696,Ergotamine
,6714270,"t 1/2,beta","The disappearance of radioactivity from blood was biphasic, with t 1/2,alpha and t 1/2,beta values of 2.9 and 16.9 h, respectively, in man and 2.9 and 14.7 h, respectively, in the rabbit.",Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),h,16.9,57905,DB00696,Ergotamine
,6714270,"t 1/2,beta","The disappearance of radioactivity from blood was biphasic, with t 1/2,alpha and t 1/2,beta values of 2.9 and 16.9 h, respectively, in man and 2.9 and 14.7 h, respectively, in the rabbit.",Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),h,14.7,57906,DB00696,Ergotamine
,6714270,Apparent volumes of distribution,Apparent volumes of distribution were 18.9 Liter/kg in man and 30.4 Liter/kg in the rabbit.,Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),[l] / [kg],18.9,57907,DB00696,Ergotamine
,6714270,Apparent volumes of distribution,Apparent volumes of distribution were 18.9 Liter/kg in man and 30.4 Liter/kg in the rabbit.,Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),[l] / [kg],30.4,57908,DB00696,Ergotamine
,7368942,infusion time,"The pharmacokinetics of dihydroergotamine (DHE) was studied in 6 beagles after a single 2.0 mg intravenous dose and after a continuous intravenous infusion (dose 2.0 mg, infusion time 51 min.=2.8-3.5 micrograms/min./kg).",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),min,51,59077,DB00696,Ergotamine
,7368942,alpha-phase T1/2,The mean alpha-phase T1/2 was 0.92 min.,The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),min,0.92,59078,DB00696,Ergotamine
,7368942,beta-phase T1/2,"and 5.93 min., the mean beta-phase T1/2 was 104.42 min.",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),min,104.42,59079,DB00696,Ergotamine
,7368942,plasma clearance,"and 115.79 min., and the mean plasma clearance value 202.88 ml/min.",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),[ml] / [min],202.88,59080,DB00696,Ergotamine
,7368942,Vdc,"Similarly, the Vdc - values were 0.121/kg and significantly from each other.",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),1/[kg],0.121,59081,DB00696,Ergotamine
,19504748,absolute bioavailability,"The absolute bioavailability and the AUC in the CSF following intranasal administration of EMSE (56.3 +/- 5.3%, AUC(CSF) 28,594 +/- 5680 ng ml(-1) min) were statistically higher than those after intranasal administration of EMS (47.4 +/- 3.5%, AUC(CSF) 19,870 +/- 2247 ng ml(-1) min).",Preparation of ergoloid mesylate submicron emulsions for enhancing nasal absorption and reducing nasal ciliotoxicity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19504748/),%,56.3,60141,DB00696,Ergotamine
,19504748,AUC(CSF),"The absolute bioavailability and the AUC in the CSF following intranasal administration of EMSE (56.3 +/- 5.3%, AUC(CSF) 28,594 +/- 5680 ng ml(-1) min) were statistically higher than those after intranasal administration of EMS (47.4 +/- 3.5%, AUC(CSF) 19,870 +/- 2247 ng ml(-1) min).",Preparation of ergoloid mesylate submicron emulsions for enhancing nasal absorption and reducing nasal ciliotoxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19504748/),[min·ng] / [ml],"28,594",60142,DB00696,Ergotamine
,19504748,AUC(CSF),"The absolute bioavailability and the AUC in the CSF following intranasal administration of EMSE (56.3 +/- 5.3%, AUC(CSF) 28,594 +/- 5680 ng ml(-1) min) were statistically higher than those after intranasal administration of EMS (47.4 +/- 3.5%, AUC(CSF) 19,870 +/- 2247 ng ml(-1) min).",Preparation of ergoloid mesylate submicron emulsions for enhancing nasal absorption and reducing nasal ciliotoxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19504748/),[min·ng] / [ml],"19,870",60143,DB00696,Ergotamine
,18179563,t(max),Post-peak (t(max) approximately 12 minutes) DHE concentrations achieved after 4 actuations ( approximately 0.88 mg respirable dose) of MAP0004 were comparable to those detected after IV administration.,Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179563/),min,12,62460,DB00696,Ergotamine
,354304,alpha-phase half-life,"Dihydroergotamine disappeared quickly from plasma, with a mean alpha-phase half-life of 1.35 min, which explained its rapid effect on blood pressure.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),min,1.35,68156,DB00696,Ergotamine
,354304,Beta-phase half-life,"Beta-phase half-life (mean 23.20 min), the volume of distribution at beta-phase (mean 0.25 I/kg), and the total plasma clearance (mean 1562.8 ml/min) indicate rapid elimination of the drug from the body.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),min,23.20,68157,DB00696,Ergotamine
,354304,volume of distribution at beta-phase,"Beta-phase half-life (mean 23.20 min), the volume of distribution at beta-phase (mean 0.25 I/kg), and the total plasma clearance (mean 1562.8 ml/min) indicate rapid elimination of the drug from the body.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),[i] / [kg],0.25,68158,DB00696,Ergotamine
,354304,total plasma clearance,"Beta-phase half-life (mean 23.20 min), the volume of distribution at beta-phase (mean 0.25 I/kg), and the total plasma clearance (mean 1562.8 ml/min) indicate rapid elimination of the drug from the body.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),[ml] / [min],1562.8,68159,DB00696,Ergotamine
,23926420,AUC(0-2h),"The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively).",Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23926420/),min·mmhg,2857,72673,DB00696,Ergotamine
,23926420,AUC(0-2h),"The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively).",Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23926420/),min·mmhg,2624,72674,DB00696,Ergotamine
,23926420,AUC(0-2h),"The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively).",Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23926420/),min·mmhg,2453,72675,DB00696,Ergotamine
,7075645,plasma levels,"Their mean plasma levels at 30 min (0.33 ng/ml) and 1 h (0.40 ng/ml) were significantly higher than those (0.06 and 0.08 ng/ml, respectively) in 9 patients with only a moderate therapeutic response.",Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075645/),[ng] / [ml],0.33,77398,DB00696,Ergotamine
,7075645,plasma levels,"Their mean plasma levels at 30 min (0.33 ng/ml) and 1 h (0.40 ng/ml) were significantly higher than those (0.06 and 0.08 ng/ml, respectively) in 9 patients with only a moderate therapeutic response.",Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075645/),[ng] / [ml],0.40,77399,DB00696,Ergotamine
,7075645,plasma levels,"Their mean plasma levels at 30 min (0.33 ng/ml) and 1 h (0.40 ng/ml) were significantly higher than those (0.06 and 0.08 ng/ml, respectively) in 9 patients with only a moderate therapeutic response.",Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075645/),[ng] / [ml],0.06,77400,DB00696,Ergotamine
,7075645,plasma levels,"Their mean plasma levels at 30 min (0.33 ng/ml) and 1 h (0.40 ng/ml) were significantly higher than those (0.06 and 0.08 ng/ml, respectively) in 9 patients with only a moderate therapeutic response.",Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075645/),[ng] / [ml],0.08,77401,DB00696,Ergotamine
,7075645,peak concentrations,The mean peak concentrations in moderate (0.13 ng/ml) and poor (0.11 ng/ml) responders appeared later (at 3 h) than in good responders (at 1 h).,Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075645/),[ng] / [ml],0.13,77402,DB00696,Ergotamine
,7075645,peak concentrations,The mean peak concentrations in moderate (0.13 ng/ml) and poor (0.11 ng/ml) responders appeared later (at 3 h) than in good responders (at 1 h).,Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075645/),[ng] / [ml],0.11,77403,DB00696,Ergotamine
,7173294,initial distribution half-life,"After intravenous administration the plasma ergotamine declined rapidly, with and initial distribution half-life of 3 min followed by a mean terminal half-life of 1.86 h (range 90-155 min).",Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173294/),min,3,80108,DB00696,Ergotamine
,7173294,terminal half-life,"After intravenous administration the plasma ergotamine declined rapidly, with and initial distribution half-life of 3 min followed by a mean terminal half-life of 1.86 h (range 90-155 min).",Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173294/),h,1.86,80109,DB00696,Ergotamine
,7173294,total plasma clearance,"The mean total plasma clearance was 11.0 ml kg-1 min-1, and the volume of distribution (Vd beta) was 1847.6 ml kg-1.",Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173294/),[ml] / [kg·min],11.0,80110,DB00696,Ergotamine
,7173294,volume of distribution (Vd beta),"The mean total plasma clearance was 11.0 ml kg-1 min-1, and the volume of distribution (Vd beta) was 1847.6 ml kg-1.",Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173294/),[ml] / [kg],1847.6,80111,DB00696,Ergotamine
,7173294,biological availability,The biological availability was incomplete and variable at 46.6% (range 28.3-60.8%).,Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7173294/),%,46.6,80112,DB00696,Ergotamine
,3173919,peak plasma levels,"For the same vaginal doses, the mean (+/- SEM) peak plasma levels were 555 +/- 164 pg/mL at 12 +/- 0.6 hours, 702 +/- 252 pg/mL at 11.2 +/- 0.9 hours, and 1055 +/- 220 pg/mL at 10.7 +/- 1.7 hours, respectively.",Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3173919/),[pg] / [ml],555,80371,DB00696,Ergotamine
,3173919,peak plasma levels,"For the same vaginal doses, the mean (+/- SEM) peak plasma levels were 555 +/- 164 pg/mL at 12 +/- 0.6 hours, 702 +/- 252 pg/mL at 11.2 +/- 0.9 hours, and 1055 +/- 220 pg/mL at 10.7 +/- 1.7 hours, respectively.",Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3173919/),[pg] / [ml],702,80372,DB00696,Ergotamine
,3173919,peak plasma levels,"For the same vaginal doses, the mean (+/- SEM) peak plasma levels were 555 +/- 164 pg/mL at 12 +/- 0.6 hours, 702 +/- 252 pg/mL at 11.2 +/- 0.9 hours, and 1055 +/- 220 pg/mL at 10.7 +/- 1.7 hours, respectively.",Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3173919/),[pg] / [ml],1055,80373,DB00696,Ergotamine
,3988387,peak plasma concentrations,The drug was rapidly absorbed from the injection site; peak plasma concentrations of 3-8 ng/ml were observed within 15-45 min of dosing.,Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[ng] / [ml],3-8,82128,DB00696,Ergotamine
,3988387,Half-lives,"Half-lives for the rapid and slow phases of decline in plasma dihydroergotamine were 0.95 and 7.26 h, respectively.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),h,0.95,82129,DB00696,Ergotamine
,3988387,Half-lives,"Half-lives for the rapid and slow phases of decline in plasma dihydroergotamine were 0.95 and 7.26 h, respectively.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),h,7.26,82130,DB00696,Ergotamine
,3988387,overall volume of distribution,The overall volume of distribution was 14.6 l/kg.,Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[l] / [kg],14.6,82131,DB00696,Ergotamine
,3988387,plasma clearance,"The plasma clearance and renal clearance values were 1814 and 91 ml/min, respectively, indicating that 5% of the dose was excreted unchanged in the urine.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[ml] / [min],1814,82132,DB00696,Ergotamine
,3988387,renal clearance,"The plasma clearance and renal clearance values were 1814 and 91 ml/min, respectively, indicating that 5% of the dose was excreted unchanged in the urine.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[ml] / [min],91,82133,DB00696,Ergotamine
,649230,alpha-phase half-life,"After single 0.5-mg nad 1.0-mg i.v. injections, dihydroergotamine, as measured by a radioimmunoassay, disappeared quickly from the plasma of beagles, with a mean alpha-phase half-life of 1.32--1.91 min.",The pharmacokinetics of dihydroergotamine in the beagle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),min,1.32,88124,DB00696,Ergotamine
,649230,beta-phase half-life,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),min,40.79,88125,DB00696,Ergotamine
,649230,volume of ditribution at beta-phase,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),[l] / [kg],1.50,88126,DB00696,Ergotamine
,649230,plasma clearance,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),[ml] / [min],311.67,88127,DB00696,Ergotamine
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,2.7,88128,DB00696,Ergotamine
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,2.3,88129,DB00696,Ergotamine
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,3.1,88130,DB00696,Ergotamine
,8841149,peak plasma levels,"Nasally administered dihydroergotamine (1 mg) becomes rapidly available to the systemic circulation, with peak plasma levels of 1 ng/ml achieved in 0.9 hour.",Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),[ng] / [ml],1,88362,DB00696,Ergotamine
,8841149,relative bioavailability,The relative bioavailability versus intramuscular route is 38.4%.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,38.4,88363,DB00696,Ergotamine
,8841149,bioavailability,Intraindividual variations of bioavailability evaluated for a 1-year period were higher (29%) than those found for the intramuscular route (20%) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,29,88364,DB00696,Ergotamine
,8841149,bioavailability,Intraindividual variations of bioavailability evaluated for a 1-year period were higher (29%) than those found for the intramuscular route (20%) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,20,88365,DB00696,Ergotamine
,8841149,bioavailability,Interindividual variations for bioavailability were greater (25% versus 14% by the intramuscular route) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,25,88366,DB00696,Ergotamine
,8841149,bioavailability,Interindividual variations for bioavailability were greater (25% versus 14% by the intramuscular route) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,14,88367,DB00696,Ergotamine
,1379152,half-life,It is likely that migraine recurrence is related to the short half-life of the drug (approximately 2 hours).,"Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379152/),h,2,90807,DB00696,Ergotamine
less,6421592,detection limit,Both antibody affinity and high specific radioactivity of tracers allow a sensitive assay (detection limit less than 20 pg/ml) in human plasma.,Highly sensitive and specific radioimmunoassays for dihydroergotoxine components in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6421592/),[pg] / [ml],20,92316,DB00696,Ergotamine
,11215321,peak,"After administration of tablets the peak of DHETM was (mean +/- SE) 124 +/- 16 pg/ml, the tmax 1.15 +/- 0.21 h, the AUC 790 +/- 93 pg/ml x h and the terminal elimination half-life 7.54 +/- 1.23 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),[pg] / [ml],124,98786,DB00696,Ergotamine
,11215321,tmax,"After administration of tablets the peak of DHETM was (mean +/- SE) 124 +/- 16 pg/ml, the tmax 1.15 +/- 0.21 h, the AUC 790 +/- 93 pg/ml x h and the terminal elimination half-life 7.54 +/- 1.23 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),h,1.15,98787,DB00696,Ergotamine
,11215321,AUC,"After administration of tablets the peak of DHETM was (mean +/- SE) 124 +/- 16 pg/ml, the tmax 1.15 +/- 0.21 h, the AUC 790 +/- 93 pg/ml x h and the terminal elimination half-life 7.54 +/- 1.23 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),[pg] / [h·ml],790,98788,DB00696,Ergotamine
,11215321,terminal elimination half-life,"After administration of tablets the peak of DHETM was (mean +/- SE) 124 +/- 16 pg/ml, the tmax 1.15 +/- 0.21 h, the AUC 790 +/- 93 pg/ml x h and the terminal elimination half-life 7.54 +/- 1.23 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),h,7.54,98789,DB00696,Ergotamine
,11215321,peak,"After oral solution the peak of DHETM was 176 +/- 16 pg/ml, the tmax 0.50 +/- 0.04 h, the AUC 779 +/- 94 pg/ml x h and the terminal elimination half-life 6.13 +/- 0.76 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),[pg] / [ml],176,98790,DB00696,Ergotamine
,11215321,tmax,"After oral solution the peak of DHETM was 176 +/- 16 pg/ml, the tmax 0.50 +/- 0.04 h, the AUC 779 +/- 94 pg/ml x h and the terminal elimination half-life 6.13 +/- 0.76 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),h,0.50,98791,DB00696,Ergotamine
,11215321,AUC,"After oral solution the peak of DHETM was 176 +/- 16 pg/ml, the tmax 0.50 +/- 0.04 h, the AUC 779 +/- 94 pg/ml x h and the terminal elimination half-life 6.13 +/- 0.76 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),[pg] / [h·ml],779,98792,DB00696,Ergotamine
,11215321,terminal elimination half-life,"After oral solution the peak of DHETM was 176 +/- 16 pg/ml, the tmax 0.50 +/- 0.04 h, the AUC 779 +/- 94 pg/ml x h and the terminal elimination half-life 6.13 +/- 0.76 h.",Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215321/),h,6.13,98793,DB00696,Ergotamine
,3436686,relative bioavailability,"The plasma concentration profile after a single 4.5 mg SR-capsule with relative bioavailability 92% (Oral solution, 4.5 mg as single dose = 100%), releasing 80% of the capsule contents within 8 h, was similar to that achieved following the application of 2-3 divided doses at 5 h intervals of a solution (relative bioavailability = 85%), standard tablet (relative bioavailability = 99%) or SR-tablets (relative bioavailability 78%).",Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436686/),%,92,107072,DB00696,Ergotamine
,3436686,relative bioavailability,"The plasma concentration profile after a single 4.5 mg SR-capsule with relative bioavailability 92% (Oral solution, 4.5 mg as single dose = 100%), releasing 80% of the capsule contents within 8 h, was similar to that achieved following the application of 2-3 divided doses at 5 h intervals of a solution (relative bioavailability = 85%), standard tablet (relative bioavailability = 99%) or SR-tablets (relative bioavailability 78%).",Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436686/),%,85,107073,DB00696,Ergotamine
,3436686,relative bioavailability,"The plasma concentration profile after a single 4.5 mg SR-capsule with relative bioavailability 92% (Oral solution, 4.5 mg as single dose = 100%), releasing 80% of the capsule contents within 8 h, was similar to that achieved following the application of 2-3 divided doses at 5 h intervals of a solution (relative bioavailability = 85%), standard tablet (relative bioavailability = 99%) or SR-tablets (relative bioavailability 78%).",Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436686/),%,99,107074,DB00696,Ergotamine
,3436686,relative bioavailability,"The plasma concentration profile after a single 4.5 mg SR-capsule with relative bioavailability 92% (Oral solution, 4.5 mg as single dose = 100%), releasing 80% of the capsule contents within 8 h, was similar to that achieved following the application of 2-3 divided doses at 5 h intervals of a solution (relative bioavailability = 85%), standard tablet (relative bioavailability = 99%) or SR-tablets (relative bioavailability 78%).",Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436686/),%,78,107075,DB00696,Ergotamine
exceeding,3436686,plateau concentrations,Application of a single 4.5 mg SR-capsule can maintain prolonged plateau concentrations exceeding 100 pg/ml over 10 h.,Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436686/),[pg] / [ml],100,107076,DB00696,Ergotamine
,3101710,bioavailability,The bioavailability of G-1-N in the rat and in the dog is practically 100%.,"[Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3101710/),%,100,107989,DB00696,Ergotamine
,1499595,area under the plasma level time curve (AUC infinity),The area under the plasma level time curve (AUC infinity) of co-dergocrine increased from 0.59 +/- 0.41 ng.ml-1. (mean +/- SD) in the normals to 1.24 +/- 0.95 ng.,Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),[ng] / [ml],0.59,110870,DB00696,Ergotamine
,1499595,area under the plasma level time curve (AUC infinity),The area under the plasma level time curve (AUC infinity) of co-dergocrine increased from 0.59 +/- 0.41 ng.ml-1. (mean +/- SD) in the normals to 1.24 +/- 0.95 ng.,Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),ng,1.24,110871,DB00696,Ergotamine
,1499595,AUC infinity,"Corresponding values for the nifedipine AUC infinity were 564.5 +/- 268 ng.ml-1.h, 1547.5 +/- 1134 (P less than 0.05) and 929 +/- 533 ng.",Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),[h·ng] / [ml],564.5,110872,DB00696,Ergotamine
,1499595,AUC infinity,"Corresponding values for the nifedipine AUC infinity were 564.5 +/- 268 ng.ml-1.h, 1547.5 +/- 1134 (P less than 0.05) and 929 +/- 533 ng.",Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),ng,1547.5,110873,DB00696,Ergotamine
,1499595,AUC infinity,"Corresponding values for the nifedipine AUC infinity were 564.5 +/- 268 ng.ml-1.h, 1547.5 +/- 1134 (P less than 0.05) and 929 +/- 533 ng.",Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),ng,929,110874,DB00696,Ergotamine
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.42,115958,DB00696,Ergotamine
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.82,115959,DB00696,Ergotamine
,3956565,half-life,This fast release process was followed by slow clearance with a half-life of 16 days.,Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956565/),d,16,123278,DB00696,Ergotamine
,3609067,biologic half-life in the elimination phase,The biologic half-life in the elimination phase was 8.35 +/- 1.87 h after oral administration and 8.84 +/- 3.64 h after intravenous administration.,Bioavailability of dihydroergosine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609067/),h,8.35,124304,DB00696,Ergotamine
,3609067,biologic half-life in the elimination phase,The biologic half-life in the elimination phase was 8.35 +/- 1.87 h after oral administration and 8.84 +/- 3.64 h after intravenous administration.,Bioavailability of dihydroergosine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609067/),h,8.84,124305,DB00696,Ergotamine
,3609067,bioavailability,The calculated bioavailability of the drug was 9.80 +/- 2.8%.,Bioavailability of dihydroergosine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609067/),%,9.80,124306,DB00696,Ergotamine
,17991308,C(max),"For both studies, ET C(max) was higher with the BSPCI (study 1: sublingual ET 134 pg/mL at 37 min; BSPCI 3743 pg/mL at 3 min; study 2: metered-dose inhaler 1109 pg/mL at 4 min; BSPCI 1210 pg/mL at 2.5 min).",Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991308/),pg,134,124454,DB00696,Ergotamine
,17991308,C(max),"For both studies, ET C(max) was higher with the BSPCI (study 1: sublingual ET 134 pg/mL at 37 min; BSPCI 3743 pg/mL at 3 min; study 2: metered-dose inhaler 1109 pg/mL at 4 min; BSPCI 1210 pg/mL at 2.5 min).",Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991308/),,3743,124455,DB00696,Ergotamine
,17991308,C(max),"For both studies, ET C(max) was higher with the BSPCI (study 1: sublingual ET 134 pg/mL at 37 min; BSPCI 3743 pg/mL at 3 min; study 2: metered-dose inhaler 1109 pg/mL at 4 min; BSPCI 1210 pg/mL at 2.5 min).",Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991308/),p,1210,124456,DB00696,Ergotamine
,17991308,Lung deposition,"Lung deposition of ET with the BSPCI was 33.5, 8.9, 11.4, and 13.2% for whole, central, intermediate, and peripheral lung, respectively, with a 1.5 peripheral : central ratio.",Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991308/),%,33.5,124457,DB00696,Ergotamine
,17991308,Lung deposition,"Lung deposition of ET with the BSPCI was 33.5, 8.9, 11.4, and 13.2% for whole, central, intermediate, and peripheral lung, respectively, with a 1.5 peripheral : central ratio.",Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991308/),%,8.9,124458,DB00696,Ergotamine
,17991308,Lung deposition,"Lung deposition of ET with the BSPCI was 33.5, 8.9, 11.4, and 13.2% for whole, central, intermediate, and peripheral lung, respectively, with a 1.5 peripheral : central ratio.",Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991308/),%,11.4,124459,DB00696,Ergotamine
,17991308,Lung deposition,"Lung deposition of ET with the BSPCI was 33.5, 8.9, 11.4, and 13.2% for whole, central, intermediate, and peripheral lung, respectively, with a 1.5 peripheral : central ratio.",Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17991308/),%,13.2,124460,DB00696,Ergotamine
,7068286,bioavailability,A comparison with intravenous application of dihydroergotoxine methanesulfonate established that the bioavailability of Redergin oral tablet (1.0 mg) is 34% and Redergin solution 38%.,Comparison of the bioavailability of Redergin tablets (1.0 mg) and Redergin solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068286/),%,34,128087,DB00696,Ergotamine
,7068286,bioavailability,A comparison with intravenous application of dihydroergotoxine methanesulfonate established that the bioavailability of Redergin oral tablet (1.0 mg) is 34% and Redergin solution 38%.,Comparison of the bioavailability of Redergin tablets (1.0 mg) and Redergin solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068286/),%,38,128088,DB00696,Ergotamine
,421728,peak concentration,"The highest and longest lasting levels were found after i.m. administration, the peak concentration being 1.94 +/- 0.34 (SEM) ng/ml at 1/2 h.","Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421728/),[ng] / [ml],1.94,131135,DB00696,Ergotamine
,421728,maximum concentrations,The corresponding maximum concentrations after oral and rectal administration were 0.36 +/- 0.08 ng/ml at 2 h and 0.42 +/- 0.09 ng/ml at 1 h.,"Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421728/),[ng] / [ml],0.36,131136,DB00696,Ergotamine
,421728,maximum concentrations,The corresponding maximum concentrations after oral and rectal administration were 0.36 +/- 0.08 ng/ml at 2 h and 0.42 +/- 0.09 ng/ml at 1 h.,"Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421728/),[ng] / [ml],0.42,131137,DB00696,Ergotamine
,29051065,area under curve (AUC),"The area under curve (AUC) value after DHE delivery by MNP (1259±917ng/mL min) was not significantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability of 97%.",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),[ng] / [min·ml],1259,132466,DB00696,Ergotamine
,29051065,relative bioavailability,"The area under curve (AUC) value after DHE delivery by MNP (1259±917ng/mL min) was not significantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability of 97%.",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),%,97,132467,DB00696,Ergotamine
,29051065,tmax,"Also, appreciable plasma levels of DHE were seen within 5min for both delivery methods and tmax value of MNPs (38±23min) showed no significant difference (p>0.05) compared to subcutaneous injection (24±13min).",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),min,38,132468,DB00696,Ergotamine
,29051065,tmax,"Also, appreciable plasma levels of DHE were seen within 5min for both delivery methods and tmax value of MNPs (38±23min) showed no significant difference (p>0.05) compared to subcutaneous injection (24±13min).",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),min,24,132469,DB00696,Ergotamine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.96,134211,DB00696,Ergotamine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.73,134212,DB00696,Ergotamine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.25,134213,DB00696,Ergotamine
,7228454,T 1/2 beta,"After a single 1.0 mg intravenous injection (n = 5) DHE quickly disappeared (T 1/2 beta = 32.9 min, Vdss = 0.33 liter/kg, Cltot = 1055.7 ml/min).",Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),min,32.9,134934,DB00696,Ergotamine
,7228454,Vdss,"After a single 1.0 mg intravenous injection (n = 5) DHE quickly disappeared (T 1/2 beta = 32.9 min, Vdss = 0.33 liter/kg, Cltot = 1055.7 ml/min).",Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[l] / [kg],0.33,134935,DB00696,Ergotamine
,7228454,Cltot,"After a single 1.0 mg intravenous injection (n = 5) DHE quickly disappeared (T 1/2 beta = 32.9 min, Vdss = 0.33 liter/kg, Cltot = 1055.7 ml/min).",Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[ml] / [min],1055.7,134936,DB00696,Ergotamine
,7228454,cumulative urinary excretion,The 32-h cumulative urinary excretion was 0.02-0.04% of the 1.0 mg intravenous dose.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),h,32,134937,DB00696,Ergotamine
,7228454,cumulative urinary excretion,The 32-h cumulative urinary excretion was 0.02-0.04% of the 1.0 mg intravenous dose.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),%,0.02-0.04,134938,DB00696,Ergotamine
,7228454,renal,In one subject renal (0.18 ml/min) and extrarenal (692.9 ml/min) clearance of DHE was calculated.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[ml] / [min],0.18,134939,DB00696,Ergotamine
,7228454,extrarenal,In one subject renal (0.18 ml/min) and extrarenal (692.9 ml/min) clearance of DHE was calculated.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[ml] / [min],692.9,134940,DB00696,Ergotamine
,6419759,maximal possible bioavailability,An estimate of the maximal possible bioavailability was found to yield a mean value of 2% (tablets); 5% (suppositories) and 6% (rectal solution).,Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6419759/),%,2,147767,DB00696,Ergotamine
,6419759,maximal possible bioavailability,An estimate of the maximal possible bioavailability was found to yield a mean value of 2% (tablets); 5% (suppositories) and 6% (rectal solution).,Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6419759/),%,5,147768,DB00696,Ergotamine
,6419759,maximal possible bioavailability,An estimate of the maximal possible bioavailability was found to yield a mean value of 2% (tablets); 5% (suppositories) and 6% (rectal solution).,Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6419759/),%,6,147769,DB00696,Ergotamine
,7093108,apparent half-time of elimination,The mean apparent half-time of elimination was 2.37 +/- 0.29 h and plasma clearance of dHE was 1002 +/- 169 ml/min.,Bioavailability of dihydroergotamine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),h,2.37,151512,DB00696,Ergotamine
,7093108,plasma clearance,The mean apparent half-time of elimination was 2.37 +/- 0.29 h and plasma clearance of dHE was 1002 +/- 169 ml/min.,Bioavailability of dihydroergotamine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),[ml] / [min],1002,151513,DB00696,Ergotamine
,7093108,apparent absorption,3 Mean apparent absorption of DHE determined from the 10 mg dose was 26.6 +/- 10% and ranged from 8.9 to 60.3%.,Bioavailability of dihydroergotamine in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,26.6,151514,DB00696,Ergotamine
,7093108,oral bioavailability,"The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively.",Bioavailability of dihydroergotamine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,0.47,151515,DB00696,Ergotamine
,7093108,oral bioavailability,"The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively.",Bioavailability of dihydroergotamine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,0.59,151516,DB00696,Ergotamine
,7093108,oral bioavailability,"The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively.",Bioavailability of dihydroergotamine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,0.52,151517,DB00696,Ergotamine
,31985049,Cmax,"In part 1, DHE plasma levels showed a dose-dependent increase, with STS101 5.2 mg reaching a mean Cmax of 1870 pg/mL with a Tmax of 23 minutes.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],1870,154039,DB00696,Ergotamine
,31985049,Tmax,"In part 1, DHE plasma levels showed a dose-dependent increase, with STS101 5.2 mg reaching a mean Cmax of 1870 pg/mL with a Tmax of 23 minutes.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),min,23,154040,DB00696,Ergotamine
,31985049,plasma concentrations,"In part 2, STS101 5.2 mg showed rapid absorption, achieving mean DHE plasma concentrations of 1230 and 1850 pg/mL at 10 and 15 minutes after administration, respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],1230,154041,DB00696,Ergotamine
,31985049,plasma concentrations,"In part 2, STS101 5.2 mg showed rapid absorption, achieving mean DHE plasma concentrations of 1230 and 1850 pg/mL at 10 and 15 minutes after administration, respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],1850,154042,DB00696,Ergotamine
,31985049,Cmax,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],2175,154043,DB00696,Ergotamine
,31985049,Cmax,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],961,154044,DB00696,Ergotamine
,31985049,AUC0-2 h,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],2979,154045,DB00696,Ergotamine
,31985049,AUC0-2 h,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],1316,154046,DB00696,Ergotamine
,31985049,AUC0-inf,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],"12,030",154047,DB00696,Ergotamine
,31985049,AUC0-inf,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],6498,154048,DB00696,Ergotamine
,31985049,AUC0-inf,"The mean AUC0-inf of STS101 5.2 mg was comparable to IM DHE (12,030 vs 13,650 h × pg/mL).","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],"12,030",154049,DB00696,Ergotamine
,31985049,AUC0-inf,"The mean AUC0-inf of STS101 5.2 mg was comparable to IM DHE (12,030 vs 13,650 h × pg/mL).","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],"13,650",154050,DB00696,Ergotamine
,3932078,clearance drug,"Ergotamine was found to be a high clearance drug, average 2.21/min/70 kg body wt.",Linear pharmacokinetics of intravenous ergotamine tartrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932078/),1/[70·kg·min],2.21,156680,DB00696,Ergotamine
,6714287,bioavailability,The areas under the curve showed that the bioavailability of the new tablet was about 30% higher (28 +/- 6.3%) than that of Hydergine forte.,Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714287/),%,30,165368,DB00696,Ergotamine
,6714287,bioavailability,The areas under the curve showed that the bioavailability of the new tablet was about 30% higher (28 +/- 6.3%) than that of Hydergine forte.,Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714287/),%,28,165369,DB00696,Ergotamine
,1769319,half-life,alpha-DHEK showed a plasma profile according to an open three-compartment pharmacokinetic model with a long half-life (mean = 5.787 h).,Pharmacokinetics of alpha-dihydroergokryptine in monkeys after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1769319/),h,5.787,166241,DB00696,Ergotamine
,6406071,bioavailability,"For all three routes of administration, a similar low (0.5-4.2%) bioavailability of ergotamine was estimated.",Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406071/),%,0.5-4.2,181532,DB00696,Ergotamine
,6428916,alpha-,"The plasma level of non-volatile radioactivity declined biphasically with alpha- and beta-phase half-lives of 2.1 h and 32.3 h, respectively.","Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428916/),h,2.1,187423,DB00696,Ergotamine
,6428916,beta-phase half-lives,"The plasma level of non-volatile radioactivity declined biphasically with alpha- and beta-phase half-lives of 2.1 h and 32.3 h, respectively.","Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428916/),h,32.3,187424,DB00696,Ergotamine
,6861791,distribution rate constants alpha,"After intravenous injection and oral administration 3H-Dihydroergosine is rapidly lost from the central compartment with distribution rate constants alpha = 0.889 h-1 and beta = 0.722 h-1, respectively.",Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861791/),1/[h],0.889,191879,DB00696,Ergotamine
,6861791,beta,"After intravenous injection and oral administration 3H-Dihydroergosine is rapidly lost from the central compartment with distribution rate constants alpha = 0.889 h-1 and beta = 0.722 h-1, respectively.",Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861791/),1/[h],0.722,191880,DB00696,Ergotamine
,6861791,t 1/2,Biological half life in the elimination phase after both application is nearly the same t 1/2 = 13.6 h.,Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861791/),h,13.6,191881,DB00696,Ergotamine
,6861791,volume of central compartment is Vc,The volume of central compartment is Vc = 3.075 l/kg and the volume of distribution Vd beta = 30.75 l/kg.,Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861791/),[l] / [kg],3.075,191882,DB00696,Ergotamine
,6861791,volume of distribution Vd beta,The volume of central compartment is Vc = 3.075 l/kg and the volume of distribution Vd beta = 30.75 l/kg.,Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861791/),[l] / [kg],30.75,191883,DB00696,Ergotamine
,6861791,fraction,"The fraction of 3H-Dihydroergosine absorbed after oral administration, calculated from areas under the curves upon oral and intravenous administration, is 31%.",Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861791/),,31,191884,DB00696,Ergotamine
,9872338,brain-to-plasma concentration ratio,"Following an i.v. dose, DHE distributed into the brain with a brain-to-plasma concentration ratio of approximately 5% at 30 min postdose.",Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872338/),%,5,195298,DB00696,Ergotamine
,9872338,PeA,The PeA value of DHE ranged from 8.6 x 10(-4) to 37.5 x 10(-4) mL min(-1) g(-1) in different brain regions.,Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872338/),[ml] / [g·min],8.6 x 10(-4),195299,DB00696,Ergotamine
,9872338,PeA,The PeA value of DHE ranged from 8.6 x 10(-4) to 37.5 x 10(-4) mL min(-1) g(-1) in different brain regions.,Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872338/),[ml] / [g·min],37.5 x 10(-4),195300,DB00696,Ergotamine
,16379666,peak,"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [l],0.28,200605,DB00696,Ergotamine
,16379666,t(max),"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,0.46,200606,DB00696,Ergotamine
,16379666,AUC(last),"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [h·l],0.39,200607,DB00696,Ergotamine
,16379666,terminal elimination half-life,"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,3.50,200608,DB00696,Ergotamine
,16379666,peak,"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [l],5.63,200609,DB00696,Ergotamine
,16379666,t(max),"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,1.04,200610,DB00696,Ergotamine
,16379666,AUC(last),"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [h·l],13.36,200611,DB00696,Ergotamine
,16379666,terminal elimination half-life,"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,3.90,200612,DB00696,Ergotamine
,6126364,bioavailability,In six volunteers bioavailability was reduced to 35% for a fast release tablet and to 17% for a sustained release preparation.,Dihydroergotamine increases the bioavailability of orally administered etilefrine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126364/),%,35,204021,DB00696,Ergotamine
,6126364,bioavailability,In six volunteers bioavailability was reduced to 35% for a fast release tablet and to 17% for a sustained release preparation.,Dihydroergotamine increases the bioavailability of orally administered etilefrine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126364/),%,17,204022,DB00696,Ergotamine
,6126364,bioavailability,The addition of dihydroergotamine (DHE) to the sustained release preparation surprisingly increased bioavailability to 61%.,Dihydroergotamine increases the bioavailability of orally administered etilefrine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126364/),%,61,204023,DB00696,Ergotamine
,7245123,halflife,The halflife of the drug averaged 2.13 h in the obese subjects and 1.36 h in the normal subjects (P less than 0.02).,Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7245123/),h,2.13,208818,DB00696,Ergotamine
,7245123,halflife,The halflife of the drug averaged 2.13 h in the obese subjects and 1.36 h in the normal subjects (P less than 0.02).,Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7245123/),h,1.36,208819,DB00696,Ergotamine
,6612697,peak plasma levels,"Subcutaneously administered dihydroergotamine (DHE) becomes rapidly and completely available to the human systemic circulation, with peak plasma levels of 1.4-3.5 ng/mL/mg achieved in less than 1 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[ng] / [mg·ml],1.4-3.5,212053,DB00696,Ergotamine
,6612697,t 1/2 alpha,"The elimination of DHE from plasma is biphasic, t 1/2 alpha = 1h, t 1/2 beta = 4-5 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),h,1,212054,DB00696,Ergotamine
,6612697,t 1/2 beta,"The elimination of DHE from plasma is biphasic, t 1/2 alpha = 1h, t 1/2 beta = 4-5 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),h,4-5,212055,DB00696,Ergotamine
,6612697,peak plasma levels,"Heparin peak plasma levels (0.3 I.U./mL by activated factor X, 0.1 I.U./mL by protamine titration with a 15,000 I.U. s.c. bolus) are achieved in 3.6 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[i·u] / [ml],0.3,212056,DB00696,Ergotamine
,6612697,peak plasma levels,"Heparin peak plasma levels (0.3 I.U./mL by activated factor X, 0.1 I.U./mL by protamine titration with a 15,000 I.U. s.c. bolus) are achieved in 3.6 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[i·u] / [ml],0.1,212057,DB00696,Ergotamine
,17941060,peaks (C(max)),"In this preliminary approach, the peaks (C(max)) of dihydroergocornine, dihydroergocryptine and dihydroergocristine were about 0.04 microg/l.",Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17941060/),[μg] / [l],0.04,213353,DB00696,Ergotamine
,17941060,peaks (C(max)),"The peaks (C(max)) of their hydroxy-metabolites were 0.98, 0.53 and 0.30 microg/l, respectively.",Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17941060/),[μg] / [l],0.98,213354,DB00696,Ergotamine
,17941060,peaks (C(max)),"The peaks (C(max)) of their hydroxy-metabolites were 0.98, 0.53 and 0.30 microg/l, respectively.",Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17941060/),[μg] / [l],0.53,213355,DB00696,Ergotamine
,17941060,peaks (C(max)),"The peaks (C(max)) of their hydroxy-metabolites were 0.98, 0.53 and 0.30 microg/l, respectively.",Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17941060/),[μg] / [l],0.30,213356,DB00696,Ergotamine
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],2.10,215026,DB00696,Ergotamine
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.96,215027,DB00696,Ergotamine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.05,215028,DB00696,Ergotamine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],1.94,215029,DB00696,Ergotamine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.91,215030,DB00696,Ergotamine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.81,215031,DB00696,Ergotamine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,16.4,222423,DB00696,Ergotamine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.541,222424,DB00696,Ergotamine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,28.0,222425,DB00696,Ergotamine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],2.00,222426,DB00696,Ergotamine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,24.0,222427,DB00696,Ergotamine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.106,222428,DB00696,Ergotamine
,11888055,overall extraction recoveries,"The overall extraction recoveries of DHE and 8'-OH-DHE were determined to be about 58 and 52% on average, respectively.",Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),%,58,223250,DB00696,Ergotamine
,11888055,overall extraction recoveries,"The overall extraction recoveries of DHE and 8'-OH-DHE were determined to be about 58 and 52% on average, respectively.",Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),%,52,223251,DB00696,Ergotamine
,11888055,ch,The chromatographic run time was approximately 2.5 min.,Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),min,2.5,223252,DB00696,Ergotamine
,11888055,run time,The chromatographic run time was approximately 2.5 min.,Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),min,2.5,223253,DB00696,Ergotamine
,1492859,terminal half-life (t1/2,"DHEC, administered intravenously at the dose of 6 mg/kg, showed a plasma profile conforming to an open two-compartment pharmacokinetic model with a long terminal half-life (t1/2 = 13.6 h).",[The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492859/),h,13.6,223601,DB00696,Ergotamine
,1492859,peak (C,The first peak (C = 37 micrograms/l) occurred at the first collection point (0.5 h) indicating a quick absorption of the drug.,[The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492859/),[μg] / [l],37,223602,DB00696,Ergotamine
,1492859,peak (C,The second peak (C = 34 micrograms/l) occurred at 2 h and may be considered an indication of an enterohepatic cycle.,[The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492859/),[μg] / [l],34,223603,DB00696,Ergotamine
,1492859,terminal half-life (t1/2,A long terminal half-life (t1/2 = 18.1 h) was observed.,[The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492859/),h,18.1,223604,DB00696,Ergotamine
,1492859,systemic clearance,An extensive biotransformation of DHEC was indicated by an almost complete absence of unchanged drug in the urine and a high systemic clearance (2.65 l.h-1 x kg-1).,[The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492859/),[l] / [h·kg],2.65,223605,DB00696,Ergotamine
,1492859,volume of distribution,A large volume of distribution (52 l.kg-1) was calculated.,[The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492859/),[l] / [kg],52,223606,DB00696,Ergotamine
,11270804,Cmax,"In patients with impaired hepatic function, the geometric mean Cmax and AUC(0-infinity) values for unchanged DHEC were 571.3 pg/ml (CV: 0.87) and 4038 pg x h/ml (CV: 1.04) and were approximately 2 times (2.04, 95% CI: 0.93 to 4.46 and 2.11, 95% CI: 0.58 to 7.73 for Cmax and AUC(0-infinity), respectively) larger than those measured in age-matched healthy controls.",Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270804/),[pg] / [ml],571.3,228839,DB00696,Ergotamine
,11270804,AUC(0-infinity),"In patients with impaired hepatic function, the geometric mean Cmax and AUC(0-infinity) values for unchanged DHEC were 571.3 pg/ml (CV: 0.87) and 4038 pg x h/ml (CV: 1.04) and were approximately 2 times (2.04, 95% CI: 0.93 to 4.46 and 2.11, 95% CI: 0.58 to 7.73 for Cmax and AUC(0-infinity), respectively) larger than those measured in age-matched healthy controls.",Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270804/),[h·pg] / [ml],4038,228840,DB00696,Ergotamine
less,6812961,detection limit,"Ergotamine was determined by means of high performance liquid chromatography with fluorescence detection--a new highly sensitive, specific method, the detection limit of which is less than 100 pg/ml for ergotamine.",Low biological availability of ergotamine tartrate after oral dosing in cluster headache. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6812961/),[pg] / [ml],100,233213,DB00696,Ergotamine
less,6812961,oral biological availability,"The oral biological availability is less than 1%, which is the maximal available fraction of unchanged ergotamine after oral administration.",Low biological availability of ergotamine tartrate after oral dosing in cluster headache. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6812961/),%,1,233214,DB00696,Ergotamine
,6685489,bioavailability,The bioavailability of IS-2-MN in the rat was 100%.,"[Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685489/),%,100,234412,DB00696,Ergotamine
,17945473,Cmax,"Following nasal delivery, EM reached a Cmax value (mean+/-SD) in plasma of 348.41+/-19.47 ng/ml and in CSF of 87.35+/-6.37 ng/ml after 107 and 20 min, respectively, while after intravenous injection, EM reached a Cmax value (mean+/-S.D.) in CSF of 54.81+/-4.92 ng/ml at 60 min and the Cmax in plasma was 1255.51+/-133.59 ng/ml.",Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17945473/),[ng] / [ml],348.41,241988,DB00696,Ergotamine
,17945473,Cmax,"Following nasal delivery, EM reached a Cmax value (mean+/-SD) in plasma of 348.41+/-19.47 ng/ml and in CSF of 87.35+/-6.37 ng/ml after 107 and 20 min, respectively, while after intravenous injection, EM reached a Cmax value (mean+/-S.D.) in CSF of 54.81+/-4.92 ng/ml at 60 min and the Cmax in plasma was 1255.51+/-133.59 ng/ml.",Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17945473/),[ng] / [ml],87.35,241989,DB00696,Ergotamine
,17945473,Cmax,"Following nasal delivery, EM reached a Cmax value (mean+/-SD) in plasma of 348.41+/-19.47 ng/ml and in CSF of 87.35+/-6.37 ng/ml after 107 and 20 min, respectively, while after intravenous injection, EM reached a Cmax value (mean+/-S.D.) in CSF of 54.81+/-4.92 ng/ml at 60 min and the Cmax in plasma was 1255.51+/-133.59 ng/ml.",Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17945473/),[ng] / [ml],54.81,241990,DB00696,Ergotamine
,17945473,Cmax,"Following nasal delivery, EM reached a Cmax value (mean+/-SD) in plasma of 348.41+/-19.47 ng/ml and in CSF of 87.35+/-6.37 ng/ml after 107 and 20 min, respectively, while after intravenous injection, EM reached a Cmax value (mean+/-S.D.) in CSF of 54.81+/-4.92 ng/ml at 60 min and the Cmax in plasma was 1255.51+/-133.59 ng/ml.",Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17945473/),[ng] / [ml],1255.51,241991,DB00696,Ergotamine
,17945473,AUC(CSF)/AUC plasma ratio,The AUC(CSF)/AUC plasma ratio (0.48+/-0.05) after intranasal delivery differed greatly from the ratio (0.14+/-0.04) observed after intravenous injection (P<0.05).,Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17945473/),,0.48,241992,DB00696,Ergotamine
,17945473,AUC(CSF)/AUC plasma ratio,The AUC(CSF)/AUC plasma ratio (0.48+/-0.05) after intranasal delivery differed greatly from the ratio (0.14+/-0.04) observed after intravenous injection (P<0.05).,Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17945473/),,0.14,241993,DB00696,Ergotamine
,11453889,DeltaAUC,"Brachial artery diameter and compliance decreased (P < 0.01); DeltaAUC (95% confidence interval) equalled -8.81 mm h (-12.97/-4.65) and -0.98 mm2 kPa(-1) h (-1.61/-0.34), respectively.","Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),h·mm,-8.81,243831,DB00696,Ergotamine
,11453889,DeltaAUC,"Brachial artery diameter and compliance decreased (P < 0.01); DeltaAUC (95% confidence interval) equalled -8.81 mm h (-12.97/-4.65) and -0.98 mm2 kPa(-1) h (-1.61/-0.34), respectively.","Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),[h] / [kpa],-0.98,243832,DB00696,Ergotamine
,11453889,Time to reach maximum plasma concentration,Time to reach maximum plasma concentration of DHE averaged 0.33 +/- 0.08 h (+/- s.e.mean); terminal half-life was 5.63 +/- 1.15 h.,"Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),h,0.33,243833,DB00696,Ergotamine
,11453889,terminal half-life,Time to reach maximum plasma concentration of DHE averaged 0.33 +/- 0.08 h (+/- s.e.mean); terminal half-life was 5.63 +/- 1.15 h.,"Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),h,5.63,243834,DB00696,Ergotamine
,6794970,plasma half-life,Mean plasma half-life was 2.15 hr and plasma clearance averaged 862 ml/min.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),h,2.15,249571,DB00696,Ergotamine
,6794970,plasma clearance,Mean plasma half-life was 2.15 hr and plasma clearance averaged 862 ml/min.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ml] / [min],862,249572,DB00696,Ergotamine
less,6794970,Peak plasma concentrations,Peak plasma concentrations ranged from less than 0.1 to 2 ng/ml.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ng] / [ml],0,249573,DB00696,Ergotamine
less,6794970,Peak plasma concentrations,Peak plasma concentrations ranged from less than 0.1 to 2 ng/ml.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ng] / [ml],2,249574,DB00696,Ergotamine
,6794970,Apparent oral absorption,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,19.5,249575,DB00696,Ergotamine
,6794970,Apparent oral absorption,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,53.3,249576,DB00696,Ergotamine
less,6794970,systemic bioavailability,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,0.1,249577,DB00696,Ergotamine
,6794970,systemic bioavailability,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,1.5,249578,DB00696,Ergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,56,249579,DB00696,Ergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,370,249580,DB00696,Ergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,0.1,249581,DB00696,Ergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,1.5,249582,DB00696,Ergotamine
,3146506,Maximal plasma concentrations,Maximal plasma concentrations of co-dergocrine after oral dosing ranged between 0.181 and 1.307 ng.,The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146506/),ng,0.181 and 1.307,252390,DB00696,Ergotamine
,3146506,Maximal urinary excretion,Maximal urinary excretion ranged between 4.7 and 9.9 micrograms.h-1 and between 0.3 and 2.3 micrograms.h-1 after intravenous and oral doses respectively.,The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146506/),[μg] / [h],4.7 and 9.9,252391,DB00696,Ergotamine
,3146506,Maximal urinary excretion,Maximal urinary excretion ranged between 4.7 and 9.9 micrograms.h-1 and between 0.3 and 2.3 micrograms.h-1 after intravenous and oral doses respectively.,The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146506/),[μg] / [h],0.3 and 2.3,252392,DB00696,Ergotamine
,3146506,Clearance,Clearance was measured as 90 +/- 22 l.h-1 and the absolute systemic availability (f) as 2.25 +/- 0.65% by using the areas under the plasma concentration-time curves extrapolated to infinity.,The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146506/),[l] / [h],90,252393,DB00696,Ergotamine
,3146506,absolute systemic availability (f),Clearance was measured as 90 +/- 22 l.h-1 and the absolute systemic availability (f) as 2.25 +/- 0.65% by using the areas under the plasma concentration-time curves extrapolated to infinity.,The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146506/),%,2,252394,DB00696,Ergotamine
,1772454,half-life,"alpha-DHEK, intravenously administered at the dose of 6 mg/kg, showed a plasma profile according to an open 3-compartment pharmacokinetic model with a long half-life (about 7.56 h).",Pharmacokinetics of alpha-dihydroergocryptine in rats after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772454/),h,7.56,255307,DB00696,Ergotamine
,1772454,t1/2el,The disposition of alpha-DHEK consisted in a fast absorption and a slow elimination (t1/2el about 6.78 h).,Pharmacokinetics of alpha-dihydroergocryptine in rats after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772454/),h,6.78,255308,DB00696,Ergotamine
,7870666,Absolute bioavailability,"Absolute bioavailability of the parent drug was 35%-40%, as determined by deconvolution and by the ratios of AUC0-infinity following intranasal and intravenous dosing.",Pharmacokinetics of intranasally-administered dihydroergotamine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870666/),%,35%-40,255453,DB00696,Ergotamine
,8050122,IGF-I,Basal mean IGF-I value for all 11 patients was 716 +/- 96 micrograms/l.,Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8050122/),[μg] / [l],716,257580,DB00696,Ergotamine
,1815973,half-life,A long terminal plasma elimination phase of unchanged DHE (half-life 15 h) was found.,Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),h,15,261324,DB00696,Ergotamine
,1815973,Plasma protein binding,Plasma protein binding was 93%.,Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),%,93,261325,DB00696,Ergotamine
,1815973,tissue distribution (Vz,"Despite extensive tissue distribution (Vz = 33 l/kg) and a high plasma clearance (CLP = 2 l/min), dose-independent linear pharmacokinetics was observed.",Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),[l] / [kg],33,261326,DB00696,Ergotamine
,1815973,plasma clearance (CLP,"Despite extensive tissue distribution (Vz = 33 l/kg) and a high plasma clearance (CLP = 2 l/min), dose-independent linear pharmacokinetics was observed.",Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),[l] / [min],2,261327,DB00696,Ergotamine
,4041556,absolute bioavailability,"The results indicated that oral doses of bromocriptine were rapidly, though incompletely (32-40 per cent), absorbed, but underwent extensive first-pass metabolism, resulting in an absolute bioavailability of only 6 per cent.",Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041556/),%,6,263926,DB00696,Ergotamine
,4041556,bioavailability,"The bioavailability increased to approximately 22 per cent in rats pretreated with the hepatic microsome inhibitor proadifen, thus suggesting the liver as the principal site of biotransformation.",Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041556/),%,22,263927,DB00696,Ergotamine
,649228,relative bioavailability,"When this parameter was compared to the solution, a relative bioavailability of approximately 80% could be calculated for both tablets.",The bioavailability of alpha-acetyldigoxin from Card-Hydergin--a fixed combination of Hydergine and acetyldigoxin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649228/),%,80,267067,DB00696,Ergotamine
,649228,absolute bioavailabilities,"Relating this data to a previously published infusion experiment, their absolute bioavailabilities amounted to about 70%.",The bioavailability of alpha-acetyldigoxin from Card-Hydergin--a fixed combination of Hydergine and acetyldigoxin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649228/),%,70,267068,DB00696,Ergotamine
,6192998,t0.5 alpha,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,1.4,270075,DB00696,Ergotamine
,6192998,t0.5 alpha,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,2.0,270076,DB00696,Ergotamine
,6192998,t0.5 beta,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,22,270077,DB00696,Ergotamine
,6192998,t0.5 beta,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,21,270078,DB00696,Ergotamine
,6192998,trough levels,DHE trough levels were about 0.5 ng/ml and were well above the assumed minimum effective value to induce venoconstriction (0.06 ng/ml).,The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),[ng] / [ml],0.5,270079,DB00696,Ergotamine
,6192998,minimum effective,DHE trough levels were about 0.5 ng/ml and were well above the assumed minimum effective value to induce venoconstriction (0.06 ng/ml).,The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),[ng] / [ml],0.06,270080,DB00696,Ergotamine
,4091992,half-life,"The plasma concentrations of dihydroergotoxine produced by the three preparations, measured using a specific and sensitive radioimmuno-assay method over 24 h, exceeded 200 pg ml-1 for approximately 5 h and decayed in a biphasic manner with a slowest measured half-life of 12-14 h.",Absorption kinetics of dihydroergotoxine following oral administration to man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091992/),h,12-14,270886,DB00696,Ergotamine
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,118,273139,DB00696,Ergotamine
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,310,273140,DB00696,Ergotamine
,9718715,limit of,"The limit of quantification and the limit of detection were 3.5 and 1.2 ng/ml, respectively.",Rapid analysis of ergovaline in ovine plasma using high-performance liquid chromatography with fluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9718715/),[ng] / [ml],3.5,273384,DB00696,Ergotamine
,9718715,limit of detection,"The limit of quantification and the limit of detection were 3.5 and 1.2 ng/ml, respectively.",Rapid analysis of ergovaline in ovine plasma using high-performance liquid chromatography with fluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9718715/),[ng] / [ml],1.2,273385,DB00696,Ergotamine
,9718715,terminal half-life,"The terminal half-life and the total clearance of the mycotoxin were found to be 23.6 min and 0.020 l/min kg-1 body mass, respectively.",Rapid analysis of ergovaline in ovine plasma using high-performance liquid chromatography with fluorimetric detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9718715/),min,23.6,273386,DB00696,Ergotamine
,9718715,total clearance,"The terminal half-life and the total clearance of the mycotoxin were found to be 23.6 min and 0.020 l/min kg-1 body mass, respectively.",Rapid analysis of ergovaline in ovine plasma using high-performance liquid chromatography with fluorimetric detection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9718715/),[l] / [kg·min],0.020,273387,DB00696,Ergotamine
,3899452,Bioavailability,Bioavailability is of the order of 5% or less by oral or rectal administration.,Clinical pharmacokinetics of ergotamine in migraine and cluster headache. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899452/),%,5,273707,DB00696,Ergotamine
,3899452,elimination of half-life,The elimination of half-life is 2 to 2.5 hours and clearance is about 0.68 L/h/kg.,Clinical pharmacokinetics of ergotamine in migraine and cluster headache. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899452/),h,2 to 2.5,273708,DB00696,Ergotamine
,3899452,clearance,The elimination of half-life is 2 to 2.5 hours and clearance is about 0.68 L/h/kg.,Clinical pharmacokinetics of ergotamine in migraine and cluster headache. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899452/),[l] / [h·kg],0.68,273709,DB00696,Ergotamine
